Sarat Chandarlapaty, MD, Oncology, New York, NY, Memorial Sloan-Kettering Cancer Center

SaratChandarlapatyMDPhD

Oncology New York, NY

Hematologic Oncology

Associate Member, Human Oncology and Pathogenesis Program, MSKCC

Dr. Chandarlapaty is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Chandarlapaty's full profile

Already have an account?

Summary

  • Dr. Sarat Chandarlapaty is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Wake Forest School of Medicine and has been in practice 15 years. He specializes in hematologic oncology.

Education & Training

  • Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer CenterFELLOWSHIP
  • New York Presbyterian Hospital
    New York Presbyterian HospitalRESIDENCY
  • Wake Forest School of Medicine
    Wake Forest School of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2019 - 2021
  • NY State Medical License
    NY State Medical License 2003 - 2021
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Liquid Biopsies: Are They Ready for Prime Time in Breast Cancer? 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • Context Therapeutics Signs Strategic Research Collaborations for Apristor® (Onapristone Extended Release) with Key Academic Leaders in the Progesterone Receptor (PR) and Breast Cancer Fields
    Context Therapeutics Signs Strategic Research Collaborations for Apristor® (Onapristone Extended Release) with Key Academic Leaders in the Progesterone Receptor (PR) and Breast Cancer FieldsAugust 08, 2018
  • Accelerated Drug Development of CDK4/6 Inhibitors May Offer New Treatments for MBC
    Accelerated Drug Development of CDK4/6 Inhibitors May Offer New Treatments for MBCJune 05, 2016
  • Journal Honors Lillian Smyth, MD, MB BCh BAO, MRCPI (Ireland), as Recipient of the 2016 Journal of Clinical Oncology Young Investigator Award
    Journal Honors Lillian Smyth, MD, MB BCh BAO, MRCPI (Ireland), as Recipient of the 2016 Journal of Clinical Oncology Young Investigator AwardMay 25, 2016
  • Join now to see all

Grant Support

  • Biologic And Therapeutic Implications Of AKT Activation In HER2+ Breast CancerNational Cancer Institute2009–2011

Professional Memberships

Hospital Affiliations